Reactivation of Graves' orbitopathy after rehabilitative orbital decompression

被引:49
作者
Baldeschi, Lelio
Lupetti, Antonella
Vu, Phung
Wakelkamp, Iris M. M. J.
Prummel, Mark F.
Wiersinga, Wilmar M.
机构
[1] Univ Amsterdam, Acad Med Ctr, Orbital Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Pisa, Dept Expt Pathol Med Biotechnol Infectivol & Epid, I-56100 Pisa, Italy
[3] Univ Amsterdam, Dept Endocrinol, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1016/j.ophtha.2006.10.036
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To present and discuss three cases of apparent reactivation of Graves' orbitopathy (GO) after orbital decompression and to evaluate the incidence of this phenomenon. Design: Observational case series and retrospective follow-up study. Participants: A few weeks after surgery 2 patients with GO (patients 1 and 2), treated at our institution with rehabilitative bony orbital decompression during the static phase of the disease showed clinical and radiologic evidence of reactivated orbitopathy. After this observation, a sample of 249 patients who had consecutively undergone the same treatment for the same reason before the second of the 2 observed patients was selected for this study. Methods: The records of the selected patients were retrospectively reviewed searching for cases presenting with clinical and radiologic evidence of GO reactivated as a consequence of any type of bony orbital decompression. Patients treated with perioperative systemic glucocorticoids or who had concurrent periorbital diseases, injuries, or surgeries, or who had immunocompromised conditions or a follow-up of <= 2 months, were excluded. Main Outcome Measures: Incidence of reactivation. Clinical history, clinical and radiologic characteristics, treatment modalities, and time course of the reactivation in patients presenting with this phenomenon. Results: Decompression surgery took place between 1994 and 2000. Eleven patients were excluded for having been treated with perioperative glucocorticoids. Only 1 patient (patient 3) presented with reactivation. The incidence of the phenomenon that we regard as reactivation of GO after rehabilitative bony orbital decompression was therefore 1.3% (3/239). In all 3 patients, the reactivation took place a few weeks after surgery, after an early normal convalescence period and could be controlled with systemic immunosuppression or orbital radiotherapy. None of the patients we report developed further episodes of reactivation during the follow-up period (mean, 7.5 years). Conclusions: Based on its clinical characteristics, we suggest naming our observation delayed decompression-related reactivation and we propose using its acronym DDRR when referring to it. Although DDRR appears to be a rare event, it is important for physicians and patients to be aware of its possible occurrence with rehabilitative decompression surgery.
引用
收藏
页码:1395 / 1402
页数:8
相关论文
共 23 条
[1]   Management of Graves' ophthalmopathy: Reality and perspectives [J].
Bartalena, L ;
Pinchera, A ;
Marcocci, C .
ENDOCRINE REVIEWS, 2000, 21 (02) :168-199
[2]   Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression - Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy [J].
Cao, HJ ;
Wang, HS ;
Zhang, Y ;
Lin, HY ;
Phipps, RP ;
Smith, TJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (45) :29615-29625
[3]   A central role of CD40 ligand in the regulation of CD4(+) T-cell responses [J].
Grewal, IS ;
Flavell, RA .
IMMUNOLOGY TODAY, 1996, 17 (09) :410-414
[4]  
Hamed L M, 1990, J Pediatr Ophthalmol Strabismus, V27, P10
[5]  
Koumas L, 2002, EUR J IMMUNOL, V32, P477, DOI 10.1002/1521-4141(200202)32:2<477::AID-IMMU477>3.0.CO
[6]  
2-U
[7]   CLINICAL-CRITERIA FOR THE ASSESSMENT OF DISEASE-ACTIVITY IN GRAVES OPHTHALMOPATHY - A NOVEL-APPROACH [J].
MOURITS, MP ;
KOORNNEEF, L ;
WIERSINGA, WM ;
PRUMMEL, MF ;
BERGHOUT, A ;
VANDERGAAG, R .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1989, 73 (08) :639-644
[8]   Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy [J].
Mourits, MP ;
Prummel, MF ;
Wiersinga, WM ;
Koornneef, L .
CLINICAL ENDOCRINOLOGY, 1997, 47 (01) :9-14
[9]   CD40 and its ligand in host defense [J].
Noelle, RJ .
IMMUNITY, 1996, 4 (05) :415-419
[10]   EFFECT OF ABNORMAL THYROID-FUNCTION ON THE SEVERITY OF GRAVES OPHTHALMOPATHY [J].
PRUMMEL, MF ;
WIERSINGA, WM ;
MOURITS, MP ;
KOORNNEEF, L ;
BERGHOUT, A ;
VANDERGAAG, R .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (05) :1098-1101